Naxitamab Study 201
Study 201 was the pivotal single-arm study behind naxitamab's approval.
Interim ORR 50% (CR 38%) in 34 evaluable; full-cohort Nature Communications 2025: ORR 50%, median DOR 6.2 months. Outpatient administration.
- 50 out of 100 people had their tumour shrink with Naxitamab + GM-CSF.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Relapsed/refractory high-risk neuroblastoma in bone/bone marrow: naxitamab + GM-CSF. People in a different situation may not see the same effect.
- Only 74 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- CompanyY-mAbs Therapeutics
Shares Naxitamab, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Naxitamab, Neuroblastoma (paediatric).
- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TermINRG staging and risk groups
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaGuaranteed-quality childhood cancer medicines free of charge in 50 countries
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- PersonAlexandra "Alex" Scott
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaA paediatric palliative care team in every childhood cancer unit
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.